Detalhe da pesquisa
1.
Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices.
Mod Pathol
; 32(8): 1106-1122, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30923345
2.
Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas.
Clin Cancer Res
; 29(8): 1423-1428, 2023 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36729110
3.
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study.
J Immunother Cancer
; 11(7)2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37487667
4.
Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib.
JCO Precis Oncol
; 52021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34250398
5.
Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers.
Cancer Discov
; 10(8): 1121-1128, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32398243
6.
Evaluating of HPV-DNA ISH as an adjunct to p16 testing in oropharyngeal cancer.
Future Sci OA
; 6(9): FSO606, 2020 Aug 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33235805
7.
Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC.
Clin Cancer Res
; 26(12): 2849-2858, 2020 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32046999
8.
New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.
Lung Cancer (Auckl)
; 8: 67-78, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28761384
9.
Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer.
Ann Transl Med
; 8(23): 1613, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33437812